Bristol-Myers Squibb Company (0R1F.L)

54,23 +1,99 (+3,80%) Alla chiusura: 04:03PM BST

Bristol-Myers Squibb Company

430 East 29th Street
14th Floor
New York, NY 10016
United States
212 546 4000
https://www.bms.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Giovanni Caforio M.D.	Chairman & CEO	5,82M	N/D	1965
Mr. David V. Elkins	Exec. VP & CFO	3,18M	1,3M	1968
Ms. Sandra Leung Esq.	Exec. VP & Gen. Counsel	2,73M	N/D	1961
Dr. Christopher S. Boerner	Exec. VP & Chief Commercialization Officer	2,61M	N/D	1971
Mr. Rupert Vessey BCH, BM, DPHIL, M.A.	Exec. VP and Pres of Research & Early Devel.	3,21M	1,45M	1966
Mr. Greg Meyers	Exec. VP and Chief Digital & Technology Officer	N/D	N/D	1973
Mr. Timothy Power	VP & Head of Investor Relations	N/D	N/D	N/D
Ms. Cari Gallman	Sr. VP & Chief Compliance and Ethics Officer	N/D	N/D	N/D
Ms. Ann M. Powell Judge	Exec. VP & Chief HR Officer	N/D	N/D	1966
Mr. Jitendra Tyagi	Head of US Drug Makers - India	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Governance aziendale

L'ISS Governance QualityScore di Bristol-Myers Squibb Company al 1 febbraio 2023 è 3. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 4; diritti degli azionisti: 2; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.